UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Commission File No. 000-23399
NOTIFICATION OF LATE FILING
(Check one)
[X] Form 10-K and Form 10-KSB Form 20-F [ ] Form 11-K [ ]
[ ] Form 10-Q and Form 10-QSB Form N-SAR [ ]
For Period Ended July 31, 2000
[ ]Transition Report on Form 10-K and Form 10-KSB
[ ]Transition Report on Form 20-F
[ ]Transition Report on Form 11-K
[ ]Transition Report on Form 10-Q and Form 10-QSB
[ ]Transition Report on Form N-SAR
For the Transition Period Ended:
Read Instructions (on back page) Before Preparing Form. Please Print or
Type. Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I--REGISTRANT INFORMATION
Full Name of Registrant: Flemington Pharmaceutical Corporation
Former Name of Registrant:
Address of Principal Executive Office (Street and Number):
31 State Highway 12, Flemington, New Jersey 08822
PART II--RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25b, the
following should be completed. (Check box if appropriate):
[ X ] (a)The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expenses;
[ X ] (b)The subject annual report, semi-annual report, transition report
on Forms 10-K, 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report
or transition report on Forms 10-Q, 10-QSB, or portion thereof
will be filed on or before the fifth calendar day following the
prescribed due date; and
(c)The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III--NARRATIVE
State below in reasonable detail the reasons why the Forms 10-K, 10-KSB, 20-F,
11-K, 10-Q,10-QSB, N-SAR, or the transition report or portion thereof, could
not be filed within the prescribed time period. (Attach Extra Sheets if Needed)
The Company has not been able to finalize the financial statements for the
Company's Annual Report on Form 10-KSB by October 30, 2000, the required
filing date, without unreasonable effort.
PART IV--OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Harry A. Dugger, III (908) 782-3431
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports)
been filed? If answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? [ ] Yes [X] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
Flemingotn Pharmaceutical Corporation
(Name of Registrant as Specified In Charter)
has caused this notification to be signed on its behalf by the undersigned
hereto duly authorized.
Dated: October 30, 2000
FLEMINGTON PHARMACEUTICAL CORPORATION
By:/s/ Harry A. Dugger
------------------------------
Harry A. Dugger, III President
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION:
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
GENERAL INSTRUCTIONS:
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25 of the
General Rules and Regulations under the Securities Exchange Act of
1934.
2. One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities
and Exchange Commission, Washington, D.C. 20549, in accordance with
Rule 0-3 of the General Rules and Regulations under the Act. The
information contained in or filed with the form will be made a matter
of public record in the Commission files.
3. A manually signed copy of the form and amendments thereto shall be
filed with each national securities exchange on which any class of
securities of the registrant is registered.
4. Amendments to the notifications must also be filed on form 12b-25 but
need not restate information that has been correctly furnished. The
form shall be clearly identified as an amendment notification.
